The California Joint Replacement Registry
|
|
- Griselda Mavis Martin
- 8 years ago
- Views:
Transcription
1 The California Joint Replacement Registry Summary The California HealthCare Foundation (CHCF), the Pacific Business Group on Health (PBGH) and the California Orthopaedic Association (COA), have collaborated to develop, pilot and expand a statewide joint replacement registry, the California Joint Replacement Registry (CJRR). The specific goals of the registry are to: Collect and report scientifically valid data on the outcomes of hip and knee replacements performed in California, including device safety and effectiveness, post-operative complication and revision rates, and patient-reported assessments of outcomes. Promote the use of performance information to guide physician and patient decisions and support programs for provider recognition and reward, thus driving quality and cost improvements through marketplace mechanisms. Business Case for CJRR Joint replacements, which accounted for $41 billion in nationwide charges in 2007, have become one of the highest volume and highest cost surgeries for both Medicare and private payers. 1 From 1990 to 2002, the rate of primary hip replacements increased by approximately 50%, while the rate of primary knee replacements almost tripled. 2 Moreover, the volume of joint replacements is expected to continue its rapid growth, with a projected 174% increase in total hip arthroplasty (THA) and a 673% increase in total knee arthroplasty (TKA) by If these estimates prove correct, annual hospital and surgeon charges for joint replacements could top $70 billion within the next five years. 3 Joint replacement registries in Europe, Australia and within U.S. health care organizations have shown that registry activities can improve surgical practices, deliver timely safety alerts, and produce better outcomes for patients. In addition to the incalculable benefits to patients from such improvements in quality, registries also save health care dollars. Sweden a country that performs two thirds as many hip replacements as California has credited their Hip Registry with saving the national health system US $140 million in direct costs over a ten year period. 4 Information from a registry can: Provide Comparative Effectiveness Data on Prosthetic Devices. Over the last decade, there has been a rapid increase in the cost of implants, without evidence of improved effectiveness. Between 1998 and 2005, the average selling price of total hip replacement components grew by 43% - even after adjusting for medical cost inflation. The price increase has been attributed in part to the marketing of devices incorporating newer technologies, although studies available to date indicate new technology outcomes comparable to those of previous generations of THA implants. 5 In fact, joint registries in Sweden 6, Australia 7, England 8, and at Kaiser Permanente 9 have shown that cementless implants one of the more recent and more highly priced innovations are associated with significantly higher revision rates. California Joint Replacement Registry 1
2 Registries provide comparative data on the clinical effectiveness of different devices, allowing hospitals to undertake a value analysis of their implant choices and share those results with their surgeons. Kaiser compared a new implant technology to those in current use, found no difference in short term outcomes, and provided feedback to surgeons that changed practice with respect to implant selection. Another US registry, the HealthEast Registry, documented differences in longevity between two knee implant bearing surfaces and estimated a per patient savings of $724 for those with the longer lasting implant. 10` Reduce Complications. Periprosthetic joint infection is among the most challenging complications of total joint arthroplasty. Treating periprosthetic infections imposes significant physical and emotional burdens on patients and a significant economic burden on payors. A study of University of California, San Francisco cost center data found hospital costs for infection related re operations and treatment to average $96,000 three times greater than their average figure for revision surgeries overall. 11 Projected trends in deep infection present cautionary signs; by 2030, the overall incidence of deep infections for hip arthroplasty is projected to rise from 1.4% to 6.5%, and that for knee arthroplasty from 1.4% to 6.8%. 12 Venous thromboembolism (VTE) manifested via deep vein thrombosis (DVT) or pulmonary embolism (PE) provides similar treatment challenges. DVT and PE may cause long term complications including event recurrence and post thrombotic syndrome, which can lead to high rates of hospital readmission (5% 14%). 17 Although rates of prophylaxis administration to combat both infection and VTE have increased substantially over the last decade, substantial controversy remains over the appropriate VTE prophylaxis regimen for arthroplasty, with different specialty physician groups debating the risk of VTE versus those of major bleeds associated with various prophylaxis guidelines. 13 With the advent of new Medicare reimbursement policies on hospital acquired conditions including surgical site infections and VTE minimizing the rates of both has become a financial, as well as a quality of care, concern to hospitals. 20 The large population on which a statewide registry will be based provides sufficient sample size for measuring the outcomes of various prophylaxis regimens, and will provide evidence based data to inform adoption of guidelines that minimize the overall risk of these complications for joint replacement patients. Reduce Revision Rates. Between 1990 and 2002, the mean hip revision burden of 17.5% and the mean knee revision burden of 8.2% did not change substantially in the U.S. 3 In contrast, Sweden credits its registry programs for reducing the national hip revision rate to 7.5% and its knee revision rate to 6.4%. 1,7,21,22 Registries reduce revision rates by: Providing comparative data on the longevity of different implant types in different patient populations. Informed device selection can maximize implant life for each patient, and delay or feasibly alleviate the need for future revision surgeries. Estimates of average hospital costs for revision surgery range from $19,000 1 to $31, Identifying the patient, surgical, health system, and device-related factors associated with revision surgery. The top reasons for hip revision include dislocation (22.5% of revisions), mechanical loosening (19.7%), and deep infection (14%). 24 Enabling early identification of device specific failures. Implant failures account for 10% of all hip revision surgeries. 24 Twice since 2001, prostheses have been recalled after patients experienced highly adverse post operative outcomes often requiring immediate re operation. In the 2001 recall case, the Swedish registry was able to identify the faulty device after it had California Joint Replacement Registry 2
3 been implanted in thirty patients. In contrast, the prosthetic was implanted into 3,000 U.S. patients before the gravity of the problem was recognized. 26 In addition to providing an early warning system around problematic implants, registries can enable timely notification in the event of a recall. Governance The registry is governed by a Steering Committee, which includes representatives from the orthopedic surgeon community, hospitals, payers, purchasers and CHCF. The Steering Committee oversees all aspects of the data reporting program, which is designed to provide timely, confidential benchmarking reports to physicians and hospitals, aggregate reports evaluating outcomes associated with device and surgical technique, and after an interval to be determined by the Steering Committee, a select set of performance data to inform patient decisions and support provider recognition programs. In August, 2011, the CJRR concluded a three month pilot phase. Three sites, representing 12 surgeons, who perform 5 percent of the hip and knee replacements in California annually, participated in the pilot phase and continue to contribute data to the registry. During 2012, the CJRR will refine its operations and expand to include six additional hospital sites. Participation requirements Participating surgeons and the hospitals where they admit patients will collaborate to submit data to the CJRR. CJRR staff work with the hospital and, if relevant, the surgeon s office staff, to identify existing sources of information and arrange for ongoing, electronic transfers. The CJRR has a standard set of data elements that include patient demographics, clinical and procedure information, device information and patient reported outcomes measures. Participating providers submit this information set on an ongoing basis. Benefits to Hospitals and Surgeons Better information. The vast array of device implant options and the wide ranging needs of patients seeking joint replacement make treatment choices increasingly complex and costly. By providing comparative information on implants and surgical techniques, registries deliver evidence based data to inform practice. Responsible performance reporting. In a health care environment moving toward the increased use of performance-based reimbursement by both Medicare and the private sector the Registry offers California surgeons the opportunity to shape the quality measurement framework for orthopedic surgery. Mechanism for submitting data to Meaningful Use, PQRS and other performance programs. Both the government and private sector are ramping up their initiatives to pay for health care services based on the quality and efficiency of care provided, rather than making reimbursements based solely on the feefor-service model. Examples include: Incentives for compliance with Meaningful Use (MU) requirements California Joint Replacement Registry 3
4 Value Based Purchasing included in Accountable Care Act Centers for Medicare and Medicaid Services Hospital Compare CMS Physician Compare California Hospital Assessment and Reporting Taskforce (CHART) Physician Quality reporting System (1.5% bonus in 2011; changing to negative incentive in later years) For more information If you are interested in joining this effort, or for more information about the CJRR, please contact: Kate Chenok Phone: The Agency for Healthcare Research and Quality. National and regional estimates on hospital use for all patients from the HCUP Nationwide Inpatient Sample (NIS). Accessed November 20, S Kurtz, F Mowat, K Ong, N Chan, E Lau, M Halpern, Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through Journal of Bone and Joint Surgery, 2005 Jul;87(7): S Kurtz, K Ong, E Lau, F Mowat, M Halpern, Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to Journal of Bone and Joint Surgery, 2007 Apr; 89(4): Henrik Malchau, Peter Herberts, Thomas Eisler, Göran Garellick and Peter Söderman. The Swedish Total Hip Replacement Register. Journal of Bone and Joint Surgery Am. 2002;84: MP Kelly, KJ Bozic. Cost drivers in total hip arthroplasty: effects of procedure volume and implant selling price. American Journal of Orthopedics, 2009 Jan;38(1):E H Malchau, G Garellick, T Eisler, J Karrholm, P Herberts, The Swedish Hip Registry, Clinical Orthopedics and Related Research No.441, pp , December Australian Centre for Health Research, A Review of Joint Replacement Surgery and its Outcomes, October N Sibanda, LP Copley, JD Lewsey, M Borroff, P Gregg, et al. Colleagues Revision Rates after Primary Hip and Knee Replacement in England between 2003 and 2006, PLoS Med 5(9): e179. doi: /journal.pmed EW Paxton, M Inacio, T Slipchenko, DC Fithian, The Kaiser Permanente National Total Joint Replacement Registry, The Permanente Journal/Summer 2008/Volume 12 No T Gioe, K Killeen, S Mehle, K Grimm. Implementation and Application of a Community Total Joint Registry. Journal of Bone and Joint Surgery Am.2006; 88: Bozic KJ, Ries MD. The impact of infection after total hip arthroplasty on hospital and surgeon resource California Joint Replacement Registry 4
5 utilization. Journal of Bone and Joint Surgery Am Aug;87(8): Steven M. Kurtz et al. Future Clinical and Economic Impact of Revision Total Hip and Knee Arthroplasty, The Journal of Bone and Joint Surgery. 2007; 89 (Supple 3): Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest Feb;135(2): SooHoo NF, Lieberman JR, Ko CY, Zingmond DS. Factors predicting complication rates following total knee replacement. Journal of Bone and Joint Surgery Am Mar;88(3): Zhan C, Kaczmarek R. Loyo Berrios N, Sangl J, Bright RA. Incidence and Short Term Outcomes of Primary and Revision Hip Replacement in the United States. Journal of Bone and Joint Surgery Am. 2007; 89: White RH, Henderson MC. Risk factors for venous thromboembolism after total hip and knee replacement surgery. Current Opinions in Pulmonary Medicine Sep;8(5): Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. Journal of Managed Care Pharmacy Jul Aug;13(6): MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deep vein thrombosis, pulmonary embolism, and post thrombotic syndrome. American Journal of Health Systems Pharmacy Oct 15;63(20 Suppl 6):S Bullano MF, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Managed Care Pharmacy Oct;11(8): The Federal Register. May 22, 2009: P. Herberts and H. Malchau. The Value of the Swedish National THR Register Improved Quality and Significant Cost Reduction. European Federation of National Associations of Orthopaedics and Traumatology (EFORT): Symposium Abstracts: SCANDINAVIAN ORTHOPEDIC REGISTERS, Helsinki 4 10 June, William J. Maloney, MD. National Joint Replacement Registries: Has the Time Come? The Journal of Bone and Joint Surgery (American) 83: (2001). 23 Bozic KJ, Katz P, Cisternas M, Ono L, Ries MD, Showstack J. Hospital resource utilization for primary and revision total hip arthroplasty. J Bone Joint Surg Am Mar;87(3): KJ Bozic, SM Kurtz, E Lau, K Ong, TP Vail, DJ Berry, MD The Epidemiology of Revision Total Hip Arthroplasty in the United States. The Journal of Bone and Joint Surgery (Am). 2009; 91: Smart Implants Could Eradicate Joint Replacement Infections Orthopaedic Research and Education Foundation, pagename=practical_feature_parvizi. Accessed: November 22, B Meier, A Call for a Warning System on Artificial Joints, New York Times, July 29, California Joint Replacement Registry 5
2007 James A Vohs Award for Quality Multiregion The Kaiser Permanente National Total Joint Replacement Registry
available online: www.kp.org/permanentejournal Original article 2007 James A Vohs Award for Quality Multiregion The Kaiser Permanente National Total Joint Replacement Registry Elizabeth W Paxton, MA Maria
More informationXARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery
XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery Fast Facts: XARELTO is a novel, once-daily, oral anticoagulant recently approved in the United States for the prevention (prophylaxis)
More informationSeptember 12, 2011. Dear Dr. Corrigan:
September 12, 2011 Janet M. Corrigan, PhD, MBA President and Chief Executive Officer National Quality Forum 601 13th Street, NW Suite 500 North Washington, D.C. 20005 Re: Measure Applications Partnership
More informationMN Community Measurement Total Knee Replacement Impact and Recommendation Document June 2010
MN Community Measurement Total Knee Replacement Impact and Recommendation Document June 2010 Degree of Impact Relevance to Consumers, Employers and Payers Annually there are over 500,000 total knee replacement
More informationPartnership for Healthcare Payment Reform Total Knee Replacement Pilot Quality Report Quarter 1 Quarter 4, 2013
Partnership for Healthcare Payment Reform Total Knee Replacement Pilot Quality Report Quarter 1 Quarter 4, 2013 Introduction This report outlines the total knee replacement pilot quality results for care
More informationRandomized, double-blind, parallel-group, multicenter, doubledummy
ABOUT RECORD STUDIES FAST FACTS RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE)
More informationHospitalizations, Early Revisions and Infections Following Joint Replacement Surgery
March 26, 2008 Hospitalizations, Early Revisions and Infections Following Joint Replacement Surgery Introduction Hip and knee replacement procedures are a treatment option for patients experiencing severe
More informationUsing CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital
Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital Jonathan Sykes MD, CMIO Jacalyn Liebowitz RN, MBA,NEA-BCFACHE VP Care Continuum Allegiance Health - Jackson, MI DISCLAIMER:
More informationGraphic courtesy of DePuy Orthopaedics, Inc. HealthEast Joint Replacement Registry: 20 Year Report
Graphic courtesy of DePuy Orthopaedics, Inc. HealthEast Joint Replacement Registry: 20 Year Report HealthEast Joint Replacement Registry: 20 Year Report Foreword HealthEast Care System began the first
More informationEmployers Centers of Excellence Network (ECEN) Frequently Asked Questions
Employers Centers of Excellence Network (ECEN) Frequently Asked Questions The Employers Centers of Excellence Network (ECEN) What is this program? Inspired by our members interest in supporting value-based
More informationPreventing Readmissions
Emerging Topics in Healthcare Reform Preventing Readmissions Janssen Pharmaceuticals, Inc. Preventing Readmissions The Patient Protection and Affordable Care Act (ACA) contains several provisions intended
More informationKaiser Permanente. National Total Joint Replacement Registry. Liz Paxton Director of Surgical Outcomes & Analysis
Kaiser Permanente National Total Joint Replacement Registry Liz Paxton Director of Surgical Outcomes & Analysis Overview Background Total Joint Replacement (TJR) Importance of establishing a TJR post-market
More informationValue-Based Purchasing
Emerging Topics in Healthcare Reform Value-Based Purchasing Janssen Pharmaceuticals, Inc. Value-Based Purchasing The Patient Protection and Affordable Care Act (ACA) established the Hospital Value-Based
More informationFor Technical Assistance with HCUP Products: Email: hcup@ahrq.gov. Phone: 1-866-290-HCUP
HCUP Projections 2003 to 2012 Report # 2012-03 Contact Information: Healthcare Cost and Utilization Project (HCUP) Agency for Healthcare Research and Quality 540 Gaither Road Rockville, MD 20850 http://www.hcup-us.ahrq.gov
More informationDATE: 06 May 2013 CONTEXT AND POLICY ISSUES
TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06
More informationHoag Orthopedic Institute If we build it, will they come?
Hoag Orthopedic Institute If we build it, will they come? James T. Caillouette, M.D. Surgeon in Chief Hoag Orthopedic Institute Chairman and President Newport Orthopedic Institute What is HOI? Current
More informationPUBLISHED VERSION PERMISSIONS. This document has been archived with permission from the editor of the Medical Journal of Australia, 26 April 2007.
PUBLISHED VERSION Graves, Stephen Ellis; Davidson, David Charles; Ingerson, Lisa; Ryan, Philip; Griffith, Elizabeth Catherine; McDermott, Brian Francis John; Pratt, Nicole Leanne The Australian Orthopaedic
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationHospital Inpatient Quality Reporting (IQR) Program
Clinical Process Measures Program Changes for Fiscal Year 2014 Beginning with January 1, 2012 discharges; hospitals will begin data collection and submission for 4 new measures. Hospitals will not be required
More informationOverview. Total Joint Replacement in the U.S. KP National Total Joint Registry EMR Tools and Outcome Assessment: A Model for Vascular Surgery?
KP National Total Joint Registry EMR Tools and Outcome Assessment: A Model for Vascular Surgery? Liz Paxton Director of Surgical Outcomes and Analysis Overview KP Total Joint Replacement Registry Background
More informationDISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION
DISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION Venous thromboembolism is the most common complication after total hip and total knee arthroplasty. In recent times members of the Australian Orthopaedic
More informationComparative Effectiveness Research
Comparative Effectiveness Research 2 Nelson F. SooHoo, MD Associate Professor UCLA Dept. of Orthopaedic Surgery 8 Objectives Define comparative effectiveness research Relevance to orthopaedic surgeons
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationHow To Take Xarelto
A patient's guide Your clinic's contact details are: Name: Contact number: Contents 2 Why have I been prescribed Xarelto? 2 What is Xarelto? 3 How do I take Xarelto? 3 What should I do if I miss a dose
More informationData Analysis Project Summary
of Introduction The notion that adverse patient safety events result in excess costs is not a new concept. However, more research is needed on the actual costs of different types of adverse events at an
More informationInvestor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
More informationCornerstone Health Care s ACO Playbook. Grace E. Terrell, MD January 17, 2012
Cornerstone Health Care s ACO Playbook Grace E. Terrell, MD January 17, 2012 Mission: To be your medical home Vision: To be the model for physician-led health care in America Values: As a physician owned
More informationPrior Authorization Guideline
Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204
More informationValue Based Care and Healthcare Reform
Value Based Care and Healthcare Reform Dimensions in Cardiac Care November, 2014 Jacqueline Matthews, RN, MS Senior Director, Quality Reporting & Reform Quality and Patient Safety Institute Cleveland Clinic
More informationEvidence-Based Aquatic Therapy
Evidence-Based Aquatic Therapy for the Total Knee Replacement Instructor: Lab demonstrations: Kim Gordon, MPT University of Alabama at Birmingham grad Awarded APTA s highest honor for aquatic PTs in 2010
More informationCost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip
Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip Replacement or Total Knee Replacement National Centre
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationAccountable Care Organizations An Operational Overview
Accountable Care Organizations An Operational Overview Chris Champ Principal cchamp@eidebailly.com 701-239-8620 1 Medicare Spending 2 1 CMS Goal Transition of Risk 60 50 40 30 20 10 0 2015 2016 2018 Percentage
More information! # %# & # ( # # )# # +# ) #,+# ( # ( #!./0 12 % + + # 3 4%. 2 // 4 / 5((6 /07347137 8 0 10/ 010 4 /09 3 % 1030
! # %# & # ( # # )# # +# ) #,+# ( # ( #!./0 12 % + + # 3 4%. 2 // 4 / 5((6 /07347137 8 0 10/ 010 4 /09 3 % 1030 : Litigation after hip and knee replacement in the National Health Service A. B. McWilliams,
More information2015 Hospital Measures
2015 Hospital Measures Vicki Tang Olson, Stratis Health David Hesse, Minnesota Department of Health Statewide Quality Reporting and Measurement System (SQRMS) Annual Update January 14, 2015 Objectives
More informationManaging Surgical Services Lines Under Accountable Care and Value-Based Purchasing. Becker s Healthcare Jeffry Peters February 28, 2013
Managing Surgical Services Lines Under Accountable Care and Value-Based Purchasing Becker s Healthcare Jeffry Peters February 28, 2013 Learning Objective How ACA/VBP changes how we measure surgical services
More informationFOI request into compliance of Trust Venous Thromboembolism (VTE) prevention policies with national VTE guidance
FREEDOM OF INFORMATION REQUEST FOI request into compliance of Trust Venous Thromboembolism (VTE) prevention policies with national VTE guidance Name: Patricia Crofton Position: Lead Nurse Acute Trust:
More informationEINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012
EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF Recorded Webcast Update for Analysts and Investors March 26, 2012 1 Webcast Presentation Agenda EINSTEIN PE Clinical Trial
More informationEDUCATIONAL PLANNING TOOL:
EDUCATIONAL PLANNING TOOL: Designing a Continuing Medical Education (CME) Activity This planning tool has been designed to lead you through the educational planning process and facilitate the collection
More informationfrequently asked questions Knee and Hip Joint Replacement Technology
frequently asked questions Knee and Hip Joint Replacement Technology frequently asked questions Knee and Hip Joint Replacement Technology Recently, you may have seen advertisements from legal companies
More informationQuality Health Care. Centers of Excellence Improving Quality Pay for Performance Literature. Quality Health Care
. Quality Health Care Centers of Excellence Improving Quality Pay for Performance Literature Quality Health Care Centers of Excellence The term Center of Excellence has been widely used and in many different
More informationThe Partnership for Patients Rebalancing Health Care 5 Tom Evans, MD November 13, 2012
The Partnership for Patients Rebalancing Health Care 5 Tom Evans, MD November 13, 2012 100 E. Grand Ave., Ste. 360 Des Moines, IA 50309-1835 Office: 515.283.9330 Fax: 515.698.5130 www.ihconline.org Sustainability
More informationProgram Description and FAQ s 2016 Medicare Shared Savings Program Year
and FAQ s 2016 Medicare Shared Savings Program Year Who is the National Rural ACO? The National Rural ACO was formed in 2013 to pool knowledge, patients, and resources so that independent community health
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationTitle: Practice variation in Japan: A cross-sectional study of patient outcomes and costs in total joint replacement procedures.
1 Title: Practice variation in Japan: A cross-sectional study of patient outcomes and costs in total joint replacement procedures. Authors: Denis A. Cortese, MD; Natalie Landman, PhD; Robert K. Smoldt,
More informationZimmer Durom Cup problems could have been discovered sooner
Zimmer Durom Cup problems could have been discovered sooner July 29th, 2008 by Austin Kirk PERMALINK An article in today s edition of the New York Times highlights the lack of tracking system in place
More informationAnti-Coagulation Therapies: A Review of Best Practices for Managing Risk
Volume 20 No. 1 Spring 2012 Anti-Coagulation Therapies: A Review of Best Practices for Managing Risk Dear Colleague: This first newsletter of 2012 deals with an important aspect of patient care the monitoring
More informationHow To Help Your Health System With The National Rural Accountable Care Consortium
and FAQ s 2016 Medicare Shared Savings Program Year Who is the National Rural Accountable Care Consortium? The National Rural Accountable Care Consortium was formed in 2013 to pool knowledge, patients,
More informationBlue Distinction Centers for Spine Surgery Program Program Selection Criteria for 2010 Mid-Point Designations
Blue Distinction Centers for Spine Surgery Program Program Selection Criteria for 200 Mid-Point Designations Evaluation is based primarily on the facility s responses to the Blue Distinction Centers for
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationCMS Quality Measurement and Value Based Purchasing Programs Kate Goodrich, MD MHS Director, Quality Measurement and Health Assessment Group, CMS
CMS Quality Measurement and Value Based Purchasing Programs Kate Goodrich, MD MHS Director, Quality Measurement and Health Assessment Group, CMS American Urological Association Quality Improvement Summit
More informationEvidence Based Practice to. Value Based Purchasing. Barb Rogness BSN MS Building Bridges May 2013
Evidence Based Practice to Value Based Purchasing Barb Rogness BSN MS Building Bridges May 2013 Why this topic? Value based Purchasing is here and not going away. It will grow by leaps and bounds. The
More informationBayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
More informationIssue Brief. Raising the Bar. Standards for Accountable Care Organizations to Truly Improve Health Care Quality and Affordability in the United States
Raising the Bar Standards for Accountable Care Organizations to Truly Improve Health Care Quality and Affordability in the United States Issue Brief Introduction Health care costs continue to rise at an
More information2. Background This indication of rivaroxaban had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Rivaroxaban, tablets, 15mg and 20mg, Xarelto Sponsor: Bayer Australia Ltd Date of PBAC Consideration: March 2013 1. Purpose of Application The application requested the
More informationHealth Information Technology and the National Quality Agenda. Daphne Ayn Bascom, MD PhD Chief Clinical Systems Officer Medical Operations
Health Information Technology and the National Quality Agenda Daphne Ayn Bascom, MD PhD Chief Clinical Systems Officer Medical Operations Institute of Medicine Definition of Quality "The degree to which
More information2010 Quality and Outcomes Report. Rose Spine Institute Rose Institute for Joint Replacement
21 Quality and Outcomes Report Rose Spine Institute Rose Institute for Joint Replacement Welcome to Rose Medical Center For 6 years, we have been dedicated to offering high quality medical care to our
More informationMedicare Program; Hospital Inpatient Prospective Payment System Proposed Rule for FY 2016 (CMS-1632-P)
June 15, 2015 VIA ELECTRONIC FILING Mr. Andrew Slavitt, Acting Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-1632-P Mail Stop C4-26-05 7500
More informationReimbursement Driving HealthCare Value, May 2014 Dublin, Ireland
Reimbursement Driving HealthCare Value, May 2014 Dublin, Ireland Professor Bob Kaplan May 2014 All health care systems around the globe face a fundamental problem. How should governments, insurance companies
More informationMedication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
More informationAlert No. 2014 6 U.S. ASR Hip Settlement Alert 5/1/14. Document Requirements for Extraordinary Injury Fund (EIF) Claims
Alert No. 2014 6 U.S. ASR Hip Settlement Alert 5/1/14 Document Requirements for Extraordinary Injury Fund (EIF) Claims 1. Introduction. Pursuant to Article 8 of the Settlement Agreement, Qualified U.S.
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Total hip replacement and resurfacing arthroplasty for the treatment of pain or disability resulting from end stage arthritis
More informationAccountable Care Organizations: What Are They and Why Should I Care?
Accountable Care Organizations: What Are They and Why Should I Care? Adrienne Green, MD Associate Chief Medical Officer, UCSF Medical Center Ami Parekh, MD, JD Med. Director, Health System Innovation,
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationBundled Episodes of Care Payments
Index: How do Bundled Payments Differ from Capitation Payments? Steps to Implementing Bundled Payments Case Studies of Bundled Payments in California How Do I Implement Bundled Payments? Benefits and Risk
More informationAccountability and Innovation in Care Delivery Models
Accountability and Innovation in Care Delivery Models Lisa McDonnel Senior Vice President, Network Strategy & Innovation, United Healthcare November 6, 2015 Today s discussion topics Vision Our strategic
More informationFROM DATA TO KNOWLEDGE: INTEGRATING ELECTRONIC HEALTH RECORDS MEANINGFULLY INTO OUR NURSING PRACTICE
FROM DATA TO KNOWLEDGE: INTEGRATING ELECTRONIC HEALTH RECORDS MEANINGFULLY INTO OUR NURSING PRACTICE Rayne Soriano MS, RN Manager of Nursing Informatics and Clinical Transformation Program Kaiser Permanente
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationBayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Outpatient Joint Replacement NMP531 Effective Date*: April 2014 Updated: April 2015 This National Medical Policy is subject to the terms in the IMPORTANT
More informationReview Article The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and Total Knee Arthroplasty
Thrombosis Volume 2013, Article ID 762310, 5 pages http://dx.doi.org/10.1155/2013/762310 Review Article The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and
More informationPRESENTATIONS/PAPERS INTERNATIONAL. RAISING STANDARDS IN JOINT ARTHROPLASTY Course Co-Chairman, The Great Debate - London, June 2013
PRESENTATIONS/PAPERS INTERNATIONAL 1998 2013 RAISING STANDARDS IN JOINT ARTHROPLASTY Course Co-Chairman, The Great Debate - London, June 2013 HOW TO CHOOSE THE RIGHT STEM FOR THE RIGHT PATIENT Corin Symposium
More informationORTHOPEDIC SURGERY NATIONAL CONFERENCE CALL. Steven M. Shapiro MD Chief Medical Officer BPIS
ORTHOPEDIC SURGERY NATIONAL CONFERENCE CALL Enclosed is a summary of the nationwide conference call hosted by Best Practices Insurance Services on 1/31/2008 for Applied Medico-Legal Solutions Risk Retention
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationJune 22, 2012. Dear Administrator Tavenner:
Submitted Electronically Marilyn Tavenner Acting Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Room 445-G Hubert H. Humphrey Building 200 Independence Avenue
More informationMeasuring and Assigning Accountability for Healthcare Spending
Measuring and Assigning Accountability for Healthcare Spending Fair and Effective Ways to Analyze the Drivers of Healthcare Costs and Transition to Value-Based Payment Harold D. Miller CONTENTS EXECUTIVE
More informationFederal Health Care Reform: Implications for Hospital and Physician partnerships. Walter Kopp Medical Management Services
Federal Health Care Reform: Implications for Hospital and Physician partnerships Walter Kopp Medical Management Services Outline Overview of federal health reform legislation Implications for Care delivery
More informationMeaningful Use: Driving Physicians to eprescribing/emr and Pharma Marketing Opportunities
Meaningful Use: Driving Physicians to eprescribing/emr and Pharma Marketing Opportunities Devin Paullin EVP, New Business Development Physicians Interactive Dan Pucci Director, Informatics Solutions Allscripts
More informationIncidence Rate of Anterior Cruciate Ligament Reconstructions
Incidence Rate of Anterior Cruciate Ligament Reconstructions Abstract Context: Anterior cruciate ligament (ACL) reconstructions are among the most common sports medicine procedures performed in the US
More informationTotal Knee Replacement Performance Measurement Set
PCPI Approved American Association of Hip and Knee Surgeons Total Knee Replacement Performance Measurement Set Final PCPI Approved January 2013 Table of Contents Executive Summary 5 Purpose of Measurement
More informationEnhanced recovery programme after TKA through multi-disciplinary collaboration
Enhanced recovery programme after TKA through multi-disciplinary collaboration ChanPK(1), ChiuKY(1), FungYK(6), YeungSS(7), NgT(8), ChanMT(5), LamR(4), WongNY(3), ChoiYY(3), ChanCW(2), NgFY(1), YanCH(1)
More informationInpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
More informationHEALTH OUTCOMES RESEARCH: A PRIMER
HEALTH OUTCOMES RESEARCH: A PRIMER Foundation for Health Services Research 1350 Connecticut Avenue, N.W., Suite 1100 Washington, DC 20036 Funding for this paper was provided by the Functional Outcomes
More informationPosition Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery
Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery Position Statement There is currently insufficient data for the (AOFAS) to recommend for or against routine VTED prophylaxis for
More informationRE: CMS 1461-P; Medicare Shared Savings Program: Accountable Care Organizations
221 MAIN STREET, SUITE 1500 SAN FRANCISCO, CA 94105 PBGH.ORG OFFICE 415.281.8660 FACSIMILE 415.520.0927 February 6, 2015 Marilyn Tavenner Administrator Centers for Medicare and Medicaid Services 7500 Security
More informationFACTORS ASSOCIATED WITH ADVERSE EVENTS IN MAJOR ELECTIVE SPINE, KNEE, AND HIP INPATIENT ORTHOPAEDIC SURGERY
FACTORS ASSOCIATED WITH ADVERSE EVENTS IN MAJOR ELECTIVE SPINE, KNEE, AND HIP INPATIENT ORTHOPAEDIC SURGERY Dov B. Millstone, Anthony V. Perruccio, Elizabeth M. Badley, Y. Raja Rampersaud Dalla Lana School
More information2014 Medicare Physician Fee Schedule Proposed Rule Quality Provisions
2014 Medicare Physician Fee Schedule Proposed Rule Quality Provisions The 2014 Medicare Physician Fee Schedule (MPFS) Notice of Proposed Rulemaking (NPRM) was published in the Federal Register on July
More informationBayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
More information1. How are you using health IT enabled clinical quality measures for internal quality improvement efforts and patients care?
1. How are you using health IT enabled clinical quality measures for internal quality improvement efforts and patients care? Sharp Rees-Stealy medical group (SRSMG), a 400-physician multispecialty group
More informationWHITE PAPER. How a multi-tiered strategy can reduce readmission rates and significantly enhance patient experience
WHITE PAPER How a multi-tiered strategy can reduce readmission rates and significantly enhance patient experience Vocera Communications, Inc. June, 2014 SUMMARY Hospitals that reduce readmission rates
More informationNew Dental Care Delivery Systems: Implications for People with Disabilities
New Dental Care Delivery Systems: Implications for People with Disabilities Paul Glassman DDS, MA, MBA Professor of Dental Practice, Director of Community Oral Heath University of the Pacific School of
More informationPatient Optimization Improves Outcomes, Lowers Cost of Care >
Patient Optimization Improves Outcomes, Lowers Cost of Care > Consistent preoperative processes ensure better care for orthopedic patients The demand for primary total joint arthroplasty is projected to
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationFact Sheet on the Resource Based Relative Value Scale (RBRVS) Fee Schedule Effective January 1, 2014
Fact Sheet on the Resource Based Relative Value Scale (RBRVS) Fee Schedule Effective January 1, 2014 1. When did the new RBRVS-based fee schedule become effective? 1.1. The RBRVS-based physician and non-physician
More informationAnalytic-Driven Quality Keys Success in Risk-Based Contracts. Ross Gustafson, Vice President Allina Performance Resources, Health Catalyst
Analytic-Driven Quality Keys Success in Risk-Based Contracts March 2 nd, 2016 Ross Gustafson, Vice President Allina Performance Resources, Health Catalyst Brian Rice, Vice President Network/ACO Integration,
More informationPopulation Health Management: Banner Health Network s Perspective. Neta Faynboym, Medical Director Banner Health Network
Population Health Management: Banner Health Network s Perspective Neta Faynboym, Medical Director Banner Health Network 29 Acute Care Hospitals BANNER AT A GLANCE Banner Health Network with 400K lives
More informationOF MEANINGFUL USE THE HIDDEN REQUIREMENTS HOSPITAL QUALITY REPORTING: Introduction. Authors: Jane Metzger, Melissa Ames and Jared Rhoads
HOSPITAL QUALITY REPORTING: THE HIDDEN REQUIREMENTS OF MEANINGFUL USE Authors: Jane Metzger, Melissa Ames and Jared Rhoads Hospitals must report on 15 required quality measures for Stage 1, using the certified
More informationClinical Supply Chain Management Optimization
Clinical Supply Chain Management Optimization WSHMMA Conference April 24, 2008 Bremerton, Washington Presented by Jamie C. Kowalski Vice President, Business Development Owens & Minor, Inc The Perfect Storm
More informationResults of Surgery in a New Lung Institute in South Texas Focused on the Treatment of Lung Cancer
Results of Surgery in a New Lung Institute in South Texas Focused on the Treatment of Lung Cancer Lung cancer accounts for 13% of all cancer diagnoses and is the leading cause of cancer death in both males
More information